Hospice News November 18, 2024
Jim Parker

The rationale behind the U.S. Justice Department’s lawsuit against Optum and Amedisys (Nasdaq: AMED) is multi-faceted, citing potential adverse impacts on competition, home-based care workers and payers.

Optum, a subsidiary of UnitedHealth Group (NYSE: UNH) in June 2023 penned its agreement to acquire Amedisys in an all-cash transaction of $101 per share, or about $3.3 billion. The transaction is expected to close this year. Last summer, DOJ began investigating potential antitrust concerns related to the deal, which culminated in a lawsuit filed last week.

The state attorneys general of Maryland, Illinois, New Jersey, and New York are also plaintiffs in the suit.

DOJ’s chief concern is that the combination of the two companies would dampen competition in the hospice and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Govt Agencies, Insurance, Mergers & Acquisitions / JV, Payer, Post-Acute Care, Provider, Trends
Village Caregiving Expands Once Again, Bringing Its Footprint Into 22 States
New C-Suite Executives Tapped to Lead Hospices in 2025
Providence’s Joint Venture With Compassus Likely Delayed Amid Concerns About Patient Care And Rural Access
Joining Forces: 2024’s Hospice Investment, Consolidation Trends
Ensign Enters Oregon, Alaska with Providence Portfolio Acquisition

Share This Article